AI assistant
Jade Biosciences, Inc. — Director's Dealing 2021
Jul 2, 2021
33383_dirs_2021-07-01_4c0fd7be-e04e-4368-8574-aace04d344a5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aerovate Therapeutics, Inc. (AVTE)
CIK: 0001798749
Period of Report: 2021-04-02
Reporting Person: NOYES TIMOTHY P (Director, Chief Executive Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-04-02 | Stock Option (Right to Buy) | $2.144 | A | 254253 | Acquired | 2031-04-01 | Common Stock (254253) | Direct |
| 2021-04-02 | Stock Option (Right to Buy) | $2.144 | A | 493381 | Acquired | 2031-04-01 | Common Stock (493381) | Direct |
| 2021-06-29 | Stock Option (Right to Buy) | $14.00 | A | 271200 | Acquired | 2031-06-28 | Common Stock (271200) | Direct |
Footnotes
F1: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split.
F2: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
F3: 25% of this option shall vest and become exercisable on February 15, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F4: 25% of this option shall vest and become exercisable on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F5: 25% of this option shall vest and become exercisable on June 29, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.